|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Stathis, Anastasios; Mey, Ulrich; Schar, Sami; Hitz, Felicitas; Pott, Christiane; Mach, Nicolas; Krasniqi, Fatime; Novak, Urban; Schmidt, Christian; Hohloch, Karin; Kienle, Dirk Lars; Hess, Dagmar; Moccia, Alden A.; Unterhalt, Michael; Eckhardt, Katrin; Hayoz, Stefanie; Forestieri, Gabriela; Rossi, Davide; Dirnhofer, Stefan; Ceriani, Luca; Sartori, Giulio; Bertoni, Francesco; Buske, Christian; Zucca, Emanuele und Hiddemann, Wolfgang
(2022):
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
In: Blood Advances, Bd. 6, Nr. 13: S. 3911-3920
Dreyling, Martin; Aurer, Igor; Federico, Massimo; Jerkeman, Mats; Kersten, Marie Jose; Linton, Kim; Mey, Ulrich; Tilly, Herve und Buske, Christian
(2021):
EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic.
In: Hemasphere, Bd. 5, Nr. 2, e529
Borchmann, Peter; Haverkamp, Heinz; Lohri, Andreas; Mey, Ulrich; Kreissl, Stefanie; Greil, Richard; Markova, Jana; Feuring-Buske, Michaela; Meissner, Julia; Duehrsen, Ulrich; Ostermann, Helmut; Keller, Ulrich; Maschmeyer, Georg; Kuhnert, Georg; Dietlein, Markus; Kobe, Carsten; Eich, Hans; Baues, Christian; Stein, Harald; Fuchs, Michael; Diehl, Volker und Engert, Andreas
(2017):
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
In: Lancet Oncology, Bd. 18, Nr. 4: S. 454-463